Terapie - Další výzkum terapeutických možností
Zkoumané možnosti terapie
Islet cell transplantation
- May be an option for some people with type 1 diabetes that is not well controlled with insulin
- Difficulties include
- Finding donors that are compatibl
- Getting the new islets to survive
- Side effects from the medications used to prevent rejection
- Success rates, defined as not needing insulin at 3 years following the procedure
- Occurred in 44% of people on registry from 2010
- In the United States, as of 2016, it is considered an experimental treatment.
- en.wikipedia.org/wiki/Type_1_diabetes#Lifestyle
Islet cell transplantation
- Started to gain momentum and, in 1989
- Dr. Raymond Rajotte and his group at the University of Alberta
- Canada’s first successful islet cell transplant
- Chronic diabetes leads to kidney failure
- Islet cell transplants were typically performed together with kidney transplants
- Which required intensive immunosuppressive regimens.
- This regime proved to be toxic to islet cell function and the islet cells quickly died
- Next 10 years, the group sought new ways
- 1998, Dr. James Shapiro joined the group
- Method to do solitary islet transplants
- Using new immunosuppressive protocols known as the Edmonton Protocol
- Used worldwide
- blog.scienceborealis.ca/canadas-gift-to-the-world-a-cure-for-diabetes-mellitus/
TTP399
- Developed as an adjunctive therapy to insulin for type 1 diabetes
- Novel, oral, once-daily glucokinase activator.
Phase II SimpliciT-1 Study
- Results in American Diabetes Association’s Diabetes Care journal on February 23.
- Two parts under a treat-to-target protocol to study the drug's safety and efficacy in T1D patients over 12 weeks of daily dosing
- After a multi-week insulin optimization and placebo run-in period.
- Treatment with 800mg of TTP399 resulted in
- Statistically significant decreases in HbA1c
- Reduction by about 40% in the frequency of severe or symptomatic hypoglycemia (low blood sugar levels)x placebo
- Abnormal serum and urine ketone levels were also observed less frequently in the TTP399 x placebo cohort.
- Adjunctive therapy that protects against the main acute, life-threatening complications of type 1 diabetes
- Maintaining or improving glycemic control
- VTV plans to present the data at A Scientific Symposium: in celebration of the 100th anniversary of the University of Toronto’s discovery of insulin, which will be held virtually, April 15 and 16, 2021.
- Hypoglycemia remains a leading cause of morbidity and potential mortality in the treatment of type 1 diabetes
- TTP399 to address this serious unmet medical need
- www.biospace.com/article/fda-grants-vtv-s-type-1-diabetes-drug-breakthrough-therapy-designation/
Vertex stem cells
- Through generating billions of stem cell-derived pancreatic beta cells
- In combination with a state-of-the-art cell delivery technology
- Pancreas normally differentiates from the endodermal germ layer
- Research in generating pancreatic tissues from stem cells mimicked the step-wise developmental signals
- Generation of stem cell-derived definitive endoderm and pancreatic progenitor tissue
- Differentiating human pancreatic progenitors into fully functional insulin-secreting beta cells in vitro
- diabetesstrong.com/cure-for-type-1-diabetes/
artificial pancreas
- 2016 continues to look promising with safety issues still being studied
- 2018 they were deemed to be relatively safe
- en.wikipedia.org/wiki/Type_1_diabetes#Lifestyle
Purdue and Indiana University injections of a solution of collagen and pancreatic cells
- For a minimally invasive therapy
Mice with medically induced type 1 diabetes
- Work within 24 hours
- Maintaining “insulin independence” for at least 90 days.
- diabetesstrong.com/cure-for-type-1-diabetes/
